|
Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genzyme; Incyte; Medscape; Merck; MSD; Pfizer; Roche; Roche/Genentech; UroToday |
|
|
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi |
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma; AstraZeneca (Inst); Bayer; Curevac (Inst); ESSA (Inst); Janssen Oncology; Orion; Sanofi |
Travel, Accommodations, Expenses - Amgen; Janssen |
|
|
Honoraria - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Sanofi |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Pfizer (Inst); Sanofi (Inst) |
|
|
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Merck; Myovant Sciences; Pfizer; Tolmar |
Speakers' Bureau - Bayer; Dendreon; Janssen |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck; MSD; Pfizer; Sanofi |
Research Funding - AstraZeneca (Inst); Roche (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Janssen; Pfizer; Roche |
|
|
Consulting or Advisory Role - Astellas Pharma; Dendreon |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Janssen; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Merck; Sanofi |
Research Funding - Astellas Pharma; Janssen; Pfizer; Sanofi |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Janssen |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; Merck |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Lundbeck (I); Novo Nordisk (I); Teva (I) |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
Employment - Astellas Pharma |
Stock and Other Ownership Interests - AstraZeneca |
|
|
Employment - Astellas Pharma |
Stock and Other Ownership Interests - Amgen (I) |
Travel, Accommodations, Expenses - Astellas Pharma |
|
|
Honoraria - Astellas Pharma; Astellas Pharma; Genentech; MLI PeerView; PER; PER; Phillips Gilmore Oncology; projects in Knowledge; Research to Practice; Research to Practice; Sanofi |
Consulting or Advisory Role - AstraZeneca; Bayer; Genentech; Pfizer |
Research Funding - AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst); Pfizer (Inst) |
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753 |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Genentech; Genentech/Roche; Pfizer |